Navigation Links
Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
Date:10/24/2013

65.0 Change in fair value of contingent consideration 14.7 1.2 28.4 3.3 Impairment of intangible assets - - 19.9 27.0 Goodwill impairment charge - - 198.9 - Gain on sale of product rights (3.6) (5.7) (14.6) (16.5) Other, net (2.8) (0.7) 4.4 1.8 Movement in deferred taxes (5.1) (6.3) 16.1 (30.4) Equity in losses/(earnings) of equity method investees 0.3 (0.2) (0.6) (0.5) Changes in operating assets and liabilities: Increase in accounts receivable (112.6) (45.4) (215.2) (23.0) Increase in sales deduction accrual 68.7 8.5 108.7 36.1 Decrease/(increase) in inventory 14.0 (14.9) (39.9) (81.9) (Increase)/decrease in prepayments and other assets (4.4) (14.3) (70.9) 17.8 Increase/(decrease) in accounts payable and other liabilities 89.3 38.3 (71.4) 72.7 Returns on investment from joint venture - - 3.2 4.9 Net cash provided by operating activities(A) 433.7 288.4 852.7 1,011.2

CASH FLOWS FROM INVESTING ACTIVITIES: Movements in restricted cash 1.0 (4.5) 0.5 1.7 Purchases of subsidiary undertakings and businesses, net of cash acquired - - (227.8) (97.0) Purchases of non-current investments (3.1) (7.4) (9.9) (12.1) Purchases of PP&E (45.3) (27.2) (110.3) (91.6) Purchases of intangible assets - - - (43.5) Proceeds received on sale of product rights 4.7 3.3 15.0 13.7 Other, net 1.0 0.1 11.5 13.2 Net cash used in investing activities(B) (41.7) (35.7) (321.0) (215.6)


Unaudited US GAAP results for the three months and nine months to September 30, 2013
Consolidated Statements of Cash Flows (continued)

3 months to 9 months to September 30, September 30, 2013 2012 2013 2012 $M $M $M $M CASH FLOWS FROM FINANCING ACTIVITIES: Payments to acquire shares under the share buy-back program (12.8) - (190.5) - Payment of dividend - - (79.2) (70.7) Payments to acquire shares by the Employee Benefit Trust ("EBT") - (40.2) (50.3) (50.9) Excess tax benefit associated with exercise of stock options 3.4 3.5 9.5 38.6 Contingent consider
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
11. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... September 23, 2014 Dr. Williams says, ... book on healthcare offers a three phase process that ... healthcare delivery system that would go far beyond anything ... regarding the delivery of healthcare.” , “Every effort to ... failed to provide discernable progress throughout that system because ...
(Date:9/22/2014)... were treated with a statin in the hospital after ... to survive than those who were not, according to ... This study was conducted by the same researchers who ... improve survival in victims of ischemic stroke., Ischemic stroke ... blood vessel that blocks blood from reaching areas of ...
(Date:9/22/2014)... LEGO-like components developed by researchers at the USC ... to build a 3-D microfluidic system quickly and ... hand. , Microfluidic systems are used in ... precisely manipulate small volumes of fluids for use ... pathogen detection, clinical diagnostic testing, and synthetic chemistry. ...
(Date:9/22/2014)... developed a unique nanoscale device that for the ... discovery could have major implications for creating faster ... communication. , The research paper by University of ... Li and his graduate student Huan Li has ... October issue of Nature Nanotechnology . , ...
Breaking Biology Technology:Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5Engineers show light can play seesaw at the nanoscale 2
... , , , ... (Medical College), a private medical school with more than 1,100 physicians, ... (SRM) solution to track, manage and report adverse and near-miss events, ... Event Manager (EM) and Claims Manager (CM) modules, part of the ...
... ... Room To Share Due Diligence Documents , ... Los Gatos, CA (PRWEB) September 16, 2009 -- Pandesa ... a number of pharmaceutical, biopharmaceutical and biotech research and development companies worldwide, to securely ...
... AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: ... endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, ... licensee for perifosine in the North American market, has ... Food and Drug Administration (FDA) for the treatment of ...
Cached Biology Technology:The Medical College of Wisconsin Adopts Quantros Event Manager(TM) and Claims Manager(TM) for Comprehensive Malpractice Litigation Management 2Pandesa ShareVault Enables Secure, Real-time Due Diligence for Biopharmaceutical Partnering 2Pandesa ShareVault Enables Secure, Real-time Due Diligence for Biopharmaceutical Partnering 3AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 2AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 3
(Date:9/23/2014)... Research and Markets  has announced the ... Opportunities, 2019" report to their offering. ... security and protection in private as well as government ... government is focusing on using biometric systems to store ... IDs that are of crucial importance to the country. ...
(Date:9/23/2014)... Newest Market IPO,s and ... for significant investor attention with news concerning shareholder updates and ... are: NXT-ID, Inc. (NASDAQ: NXTD ), Alibaba Group ... MBLY ), GoPro, Inc. (NASDAQ: GPRO ... Inc. (NASDAQ: NXTD ) recently completed an essential ...
(Date:9/23/2014)... parasitic DNA fragments called "jumping genes" that insert themselves ... And that phenomenon can result in age-related diseases such ... now report that the "jumping genes" in mice become ... stops keeping them in check in order to take ... today in Nature Communications , Professor of Biology ...
Breaking Biology News(10 mins):India Biometrics Market Forecast and Opportunities, 2019 2India Biometrics Market Forecast and Opportunities, 2019 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7A multi-function protein is key to stopping genomic parasites from 'jumping' 2
... therapies similar to those used for HIV patients may be the ... the University of Leeds. A study of a protein called ... the protein between virus strains - known as genotypes - ... function. The p7 protein assists the spread of HCV ...
... U.S. Department of Energy Joint Genome Institute (DOE JGI) ... (Glycine max) genetic code, making it widely available to ... one of the world,s most valuable plant commodities. ... world,s edible protein, but also is an emerging feedstock ...
... DECEMBER 8, 2008 Animal feeding operations are an ... and carbon dioxideknown greenhouse gases. Recent inventories suggest ... global methane emissions. As a consequence, greenhouse gas ... the development and sustainability of animal production and ...
Cached Biology News:Leeds research points to new therapy for hepatitis C treatment 2DOE Joint Genome Institute completes soybean genome 2DOE Joint Genome Institute completes soybean genome 3Oil spray reduces greenhouse gas emissions from pig finishing barns 2
Defender against cell death 1...
Request Info...
... Hypothetical protein FLJ20644, likely ortholog of ... Protein Accession #: NP_060387.1 gi ... Definition: chromosome 14 open reading frame ... gene g4-1 [Homo sapiens] Locus ...
1/4" to 1/8" Adapter for Reflectance Probe Holder...
Biology Products: